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Abstract
Myocardial infarction (MI) induces a sterile inflammatory response which contributes to adverse 
cardiac remodeling. The initiating mechanisms of this response remain incompletely defined. We 
found that necrotic cardiomyocytes released a heat-labile pro-inflammatory signal activating MAP 
kinases and NF-κB in cardiac fibroblasts, with secondary production of cytokines. This response 
was abolished in Myd88−/− fibroblasts, but was unaffected in nlrp3-deficient fibroblasts. Despite 
MyD88-dependency, the response was TLR-independent, as explored in TLR reporter cells, 
pointing to the implication of the IL-1 pathway. Indeed, necrotic cardiomyocytes released IL-1α, 
but not IL-1β, and the immune activation of cardiac fibroblasts was abrogated by an IL-1 receptor 
antagonist and an IL-1α blocking antibody. Moreover, immune responses triggered by necrotic 
Il1a−/− cardiomyocytes were markedly reduced. In vivo, mice exposed to MI released IL-1α in 
the plasma, and post-ischemic inflammation was attenuated in Il1a−/− mice. Thus, our findings 
identify IL-1α as a crucial early danger signal triggering post-MI inflammation.
INTRODUCTION
Myocardial infarction (MI) triggers an inflammatory response aimed at healing the infarct, 
but which may also foster the process of ventricular remodeling leading to cardiac 
dysfunction (1). It is acknowledged that such inflammation is triggered by danger signals 
(damage-associated molecular patterns, or DAMPs) released by necrotic myocardium and 
sensed by pattern receptors from the TLR and the NLR families in neighbor cells (2). 
Although some contributing role to these processes has been proposed for TLR2, TLR3, 
TLR4 (reviewed in (3)) and NLRP3 (4), as well as for DAMPs such as HMGB1 or S-100 
proteins (5), the very proximal signal triggering inflammation in the ischemic heart has not 
NIH Public Access
Author Manuscript
J Immunol. Author manuscript; available in PMC 2016 January 15.
Published in final edited form as:
J Immunol. 2015 January 15; 194(2): 499–503. doi:10.4049/jimmunol.1401948.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
been established. Therefore, the present study was designed to identify the nature of this 
signal and its sensing mechanisms.
MATERIAL AND METHODS
Animal experiments were approved by our institutional review board (authorizations 2477, 
2484, 2664).
Mice, cells and treatments
Wild type mice in this study were C57BL6/J (Janvier Labs, Le Genest-Saint-Isle, France). 
Myd88−/− (a gift from Dr Thierry Roger, Lausanne University, Switzerland), Nlrp3−/− 
(obtained from Prof. Pascal Schneider, Lausanne University) and Il1a−/− (obtained from 
Prof. Yoichiro Iwakura, Tokyo University of Science) mice were backcrossed into 
C57BL6/J. Mouse neonatal ventricular cardiomyocytes (CMCs) and cardiac fibroblasts 
(CFs) were isolated by differential plating and cultured as described (6). Some experiments 
were done using cells isolated from adult mouse hearts immediately after differential plating 
and before culture, to separate CMCs from all non myoycte cells (containing CFs, vascular 
cells and some resident macrophages). For all experiments, cells were maintained in 
modified PBS-glucose buffer (PBS-G) (7). Necrosis of cells was done by 2 cycles of freeze/
thaw lysis or by exposure to H2O2 (250 μM, 20 min), confirmed by propidium iodide 
staining and troponin release (troponin T immunoassay, Roche Diagnostics) (8). 
Conditioned media (2ml) were obtained by necrosis of 8×105 cells and cleared by 
centrifugation (10 min, 13000 rpm, 4 °C). Anakinra (Swedish Orphan Biovitrum AB) and 
IL-1α blocking antibody (eBioscience) were used at 0.01–10 μg/ml. Heat inactivation of 
conditioned media was done by heating 1h at 95 °C. DNase I (Roche) was used at 10 μg/ml. 
Salmonella LPS (Sigma) was used at 1 μg/ml.
RNA analyses by Real Time PCR
RNA was reversed transcribed and RT PCR was performed using standard procedures. Gene 
expressions were normalized to endogenous controls (Rpl19, Gapdh or Rps18). The list of 
oligonucleotides is given in table S1.
Cytokines, creatine kinase and troponin
CCL2/MCP1, IL-6 and IL-1α were measured by commercial ELISAs (R&D Systems and 
Biolegend). Plasma CK and troponin were assayed using a Cobas 8000 automated analyzer 
(Roche).
Western immunoblotting
Nuclear and cytosolic proteins were immunoblotted as described (7) using primary 
antibodies against ERK1/2, phospho-ERK1/2, p38, phospho-p38, JNK, phospho-JNK, 
phospho-cJUN (Cell Signaling Technology), NF-κB p65 (Santa Cruz Biotechnology), IL-1, 
TATA-binding protein (Abcam) and Tubulin (Sigma).
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Cardiac myeloperoxidase (MPO) activity
MPO was measured in myocardial extracts using tetramethylbenzidine and H2O2, as 
described (9), and was expressed in mU/mg proteins.
Electromobility shift assay (EMSA)
Nuclear proteins (10 μg) were incubated with an [α-32P]dATP-labeled NF-κB probe (5′-
GGCAGTTGAAGGGGACTTTCCCAGG-3′), and EMSA was performed as described (7).
TLR assay
HEK-293 cell lines overexpressing a given murine TLR protein and an inducible NF-κB 
reporter gene (HEK-Blue™ TLR cells assay, InVivoGen, Toulouse, France), were treated 
with conditioned media from necrotic or living CMCs for 4h. Specific TLR ligands were 
used as positive controls. TLR-negative, TNF-sensitive cells expressing the reporter gene 
only were used as negative controls.
Mouse myocardial infarction
Myocardial ischemia (30 min) and reperfusion (2h) was performed as described (8). At the 
end of reperfusion, blood and heart were obtained for measurement of cytokines. Area at 
risk (AAR in % of left ventricle, LV) and infarct size (in % of AAR or LV), were 
determined using standard Evan’s Blue/TTC staining (8).
Data analyses
Statistical analyses were done using GraphPad Prism 6.0 software. Student t-test was used 
for simple comparisons. Multiple comparisons were done with ANOVA followed by 
Dunnet’s or Bonferroni’s posttests. A p value <0.05 was considered statistically significant.
RESULTS AND DISCUSSION
In a first series of experiments, we determined whether dying cardiomyocytes (CMCs) 
release one or more factors able to trigger innate immune responses in cardiac fibroblasts 
(CFs), which may represent “sentinel cells” to detect CMCs damage (10). Mouse neonatal 
CMCs were killed by H2O2 (8), or by freeze-thaw lysis (11), and necrosis was confirmed by 
propidium iodide staining and troponin release (Fig. 1, A–B). CFs exposed to conditioned 
medium obtained from these necrotic CMCs displayed strong transcriptional activation and 
release of the chemokine CCL2 and the cytokine IL-6 (Fig. 1, C–E), associated with the 
activation of ERK, JNK, p38, NF-κB and AP-1 (Fig. 1, F–H). Since nucleic acids and 
proteins are two major families of DAMPs (5), we evaluated whether the pro-inflammatory 
activity released by CMCs would be altered by treatment with DNAse or by heating to 
denaturate proteins. The stimulated transcription of Ccl2 and Il6 was unaffected by DNAse, 
but was eliminated by heating (Fig. 2, A–B), supporting a protein origin of the DAMP in the 
medium. These findings indicate that one or more soluble, heat-sensitive, DAMPs released 
by necrotic CMCs promote an immediate, reflex, innate immune response in CFs, which 
could therefore represent a primary source of inflammatory cytokines during MI.
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Recent studies indicated that TLR2, TLR3, TLR4 (3) and NLRP3 (4) participate to the 
cardiac response to ischemia. To explore the role of TLRs or NLRP3 in our model, we 
examined the response to necrotic CMCs of CFs deficient either in the TLR adapter MyD88, 
or in Nlrp3. Transcriptional activation of Ccl2 and Il6 was suppressed in Myd88−/− CFs 
(Fig. 2, C), suggesting an instrumental role of a TLR-mediated process, consistent with 
previous findings implicating MyD88 in post-MI inflammation (12). In contrast, there was 
no significant influence of Nlrp3 deficiency (Fig. 2, D), arguing against a role of this 
receptor in early detection of necrotic CMCs by CFs. This is at variance with a recent study 
reporting NLRP3 activation in CFs 3 days after MI (4), suggesting that NLRP3 engagement 
is a delayed, but not immediate, event in post-MI immune response.
To explore further the role of TLRs, we examined the pro-inflammatory activity of 
conditioned medium in TLR-deficient HEK 293 reporter cells selectively transfected with 
several TLR family members (except TLR1 and TLR6, expressed at low levels in native 
HEK 293 cells). Unexpectedly, conditioned medium did not activate any of the TLR-
transfected cells (Fig. 2, E), implicating the participation of an alternative MyD88-
dependent signaling cascade in CFs. Besides TLRs, MyD88 is a crucial adapter downstream 
of the IL-1 receptor 1 (IL-R1), primarily activated by one of the two isoforms of IL-1, IL-1α 
and IL-1β (13). IL-1α is present in various cell types as a fully active cytoplasmic precursor, 
whereas IL-1β is present as a precursor activated upon proteolytic processing (13). In the 
heart, relative expression of the two ligands within the different cell populations is unknown. 
We found IL-1α strongly expressed in CMCs, while it was not detected in CFs, and only 
weakly detected in the whole population of non myocyte cells (NMCs) (Fig. 3, A–D), 
supporting that cardiac IL-1α expression is mainly restricted to CMCs. In contrast, both 
CMCs and CFs expressed IL-1β mRNA (Fig. 3, E), as well as the IL-1β precursor, but 
neither cell type displayed detectable levels of mature IL-1β, even when stimulated with 
LPS, which enhanced pro-IL-1β expression (Fig. 3, F–G). CFs were able to secrete IL-1β 
when co-stimulated with LPS and nigericin, a NLRP3 activator, but did not do so when 
exposed to conditioned medium from necrotic CMCs (Fig. 3, G), which is an additional 
indication that CFs do not detect CMCs-derived signals via NLRP3.
These findings prompted us to evaluate whether IL-1α was the DAMP activating CFs in our 
model. Both the IL-1R antagonist Anakinra (14) and an IL-1α blocking antibody almost 
suppressed the induced expression of CCL2/MCP-1 and IL-6 in CFs (Fig. 3, H), implicating 
IL-1α as a crucial pro-inflammatory danger signal released by CMCs. This is in line with 
two previous investigations reporting a role of IL-1α in the neutrophilic inflammation 
elicited in mice by the implantation of dead cells and extracts of necrotic tissue (15, 16). 
Such a role of IL-1α was further demonstrated by the striking attenuation of CFs immune 
activation upon stimulation with conditioned medium obtained from CFs (instead of CMCs) 
-which lack IL-1α- (Fig. 3, I), or from CMCs genetically deficient in IL-1α (Fig. 4, A).
We next sought to determine whether a similar pro-inflammatory function of IL-1α would 
also take place during myocardial infarction in vivo, using a murine model of myocardial 
ischemia and reperfusion (MIR). The expression of IL-1α in the myocardium was detected 
at similar levels under physiological conditions, after sham surgery or after MIR (Fig. 4, B), 
implying that IL-1α is not up-regulated by MIR. In contrast, we found that IL-1α was 
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detectable in plasma only after MIR, suggesting its passive release from the necrotic 
myocardium (Fig. 4, C). When MIR was induced in Il1a null mice, the degree of myocardial 
injury was not different from WT mice (comparable infarct size and circulating levels of CK 
and troponin, Fig. 4, D–F). Notwithstanding this comparable tissue damage, Il1a−/−mice 
developed significantly less inflammation following MIR, as shown by marked reduction of 
plasma and myocardial cytokines (Fig. 4, G–I), as well as suppressed myocardial neutrophil 
infiltration (evaluated by MPO activity, Fig. 4J).
Our results identify IL-1α, released by dead CMCs and sensed by CFs, as a crucial danger 
signal in the initiation of sterile inflammation in the infarcted heart. In contrast, our studies 
do not support a role for TLR- or NLR-dependent mechanisms in such initiating process, 
although it must be underscored that our experiments using TLR-expressing HEK 293 cells 
may be criticized, as this represents an artificial in vitro system which cannot rule out a role 
for potential TLR ligands in the in vivo setting. It is also worth to mention that our results do 
not exclude the involvement of additional signals which may be active in vivo, such as the 
autonomous nervous system, the renin-angiotensin system and possibly other yet to be 
identified signals. Taking these limitations into account, our observations have potential 
clinical implications, as they provide a conceptual framework for the development of novel 
pharmacological compounds with a highly specific target in patients with acute myocardial 
infarction. Such compounds could prevent adverse ventricular remodeling by interrupting a 
proximal trigger of excessive inflammatory responses, while leaving unaltered innate 
immune defenses essential for antimicrobial resistance.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Conditioned medium from necrotic cardiomyocytes trigger innate immune responses 
in cardiac fibroblasts in vitro
(A–B) Cardiomyocyte (CMCs) necrosis (A: nuclear PI staining, B: troponin T release) 
induced by H2O2 (250 μM, 20 min) or freeze/thaw (FT). CMCs in culture medium or in 
PBS-glucose (PBS-G) served as controls (N=3–5 per conditions). (C–D) mRNA of Ccl2 and 
Il6 in cardiac fibroblasts (CFs) exposed to conditioned medium from CMCs killed by H2O2 
(CM-H2O2) or freeze/thaw (CM-FT) (N=3–7). CFs in PBS-G for 4 h served as controls. (E) 
MCP-1 and IL-6 release by CFs exposed (8 h) to CM-FT or PBS-G (N=4). (F) 
Phosphorylation of ERK, JNK and p38, (G) Cytoplasmic/nuclear NF-κB p65 and nuclear 
phospho-c-Jun, (H) NF-κB-DNA binding activity (EMSA) in CFs exposed to CM-FT. 
Tubulin and TBP (TATA-binding protein), loading control (F, G). LPS (1μg/ml, 60 min) 
was a positive control in G–H. U, untreated. Data representative of at least 3 independent 
experiments. * p<0.05. ** p<0.01. *** p<0.001.
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Figure 2. Necrotic cardiomyocytes release a heat sensitive DAMP, triggering MyD88-dependent, 
NLRP3- and TLR-independent signaling pathways in cardiac fibroblasts
(A–B) Ccl2 and Il6 mRNA in cardiac fibroblasts (CFs) exposed (4 h) to conditioned 
medium from necrotic cardiomyocytes (CM-FT), with or without DNaseI or heat 
inactivation (HI). CFs in PBS-glucose (PBS-G, 4 h) served as controls (N=3). (C–D) Ccl2 
and Il6 mRNA in wild-type (WT) versus Myd88−/− (C) or Nlrp3−/− (D) CFs stimulated for 
(1 to 4 h) with CM-FT (N=3–4). (E) HEK-TLR assay in response to TLR agonists or to 
conditioned medium obtained from live (CM-Ctl) or necrotic (CM-FT) cardiomyocytes 
(N=2). * p<0.05. ** p<0.01. *** p<0.001.
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Figure 3. IL-1α is a major alarmin specifically released by necrotic cardiomyocytes
(A) Il1a mRNA and (B) IL-1α protein in neonatal cardiomyocytes (CMCs, N=3) and 
cardiac fibroblasts (CFs, N=3). (C) IL-1α in conditioned media (CM-FT) obtained from 
necrotic CMCs or necrotic CFs (N=3). (D) IL-1α in adult cardiomyocytes (CMCs) and 
cardiac non myocyte cells (NMCs) (N=4). (E) Il1b mRNA in CMCs and CFs (N=3). (F) 
Pro-IL-1β and mature IL-1β (p17) in total cell lysates from CMCs either untreated (Ctrl) or 
stimulated with LPS (100 ng/ml, 18 h), and in conditioned medium from necrotic CMCs 
(CM-FT). Supernatants of bone-marrow macrophages (BMM) stimulated (18 h) with LPS 
(100 ng/ml) and nigericin (Nig, 5 μM) were used as positive control (N= 3). (G) Pro-IL-1β 
and mature IL-1β in total cell lysates from CFs, either left untreated (Ctrl) or stimulated (18 
h) with LPS (100 ng/ml) or LPS and nigericin (Nig, 5 μM), and in the supernatants of CFs 
untreated (Ctrl) or exposed to CM-FT from necrotic CMCs (1 and 4 h). IL-1β in 
supernatants from CFs stimulated with LPS and nigericin (Nig) was used as a positive 
control (N= 3). (H) MCP-1 and IL-6 release by CFs stimulated (4 h) with CM-FT in 
presence or absence of Anakinra or IL-1α blocking antibody (0.01–10 μg/ml) (N=3). Levels 
of MCP-1 and IL-6 in CM-FT are shown as control. (I) Ccl2 and Il6 mRNA in CFs exposed 
(1 and 4 h) to conditioned media (CM-FT) from necrotic CMCs (CMCs→CFs) or necrotic 
CFs (CFs→CFs) (N=9). * p<0.05. ** p<0.01. *** p<0.001.
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Figure 4. Crucial role of IL-1α in the acute inflammatory response after myocardial infarction
(A) MCP-1 and IL-6 release by cardiac fibroblasts (CFs) exposed 4 h to PBS-glucose (PBS-
G) or to conditioned medium from wild-type (CM-FT WT) and Il1a−/− (CM-FT Il1a−/−) 
necrotic CMCs (N=3). MCP-1 and IL-6 in CM-FT WT and CM-FT Il1a−/− shown as 
controls. (B–C) IL-1α in myocardial tissue (B) and plasma (C) of mice in baseline 
conditions (base), and after myocardial ischemia (30 min) and reperfusion (2h, MIR) or 
sham ischemia (N=4–5/group). (D) Myocardial area at risk (AAR) and infarct size (IS), in % 
of AAR or left ventricle (LV) (N= 4/group). Plasma CK (E), troponin (F), IL-6 (G), 
Myocardial MCP-1(H), IL-6 (I) and MPO activity (J) in WT and Il1a−/− mice in baseline 
conditions (Base) and after MIR (N=5–6/group). *p<0.05. **p<0.01. ***p<0.001.
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